Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay

Protein Expression and Purification

Volumn 19, Issue 1, 2000, Pages 12-21

  Xiao, Zhen ^a   Jiang, Xi ^a   Beckett, Mary Lou ^a   Wright Jr , George L ^a  

^a Sentara Cancer Resource Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFFINITY CHROMATOGRAPHY; ANTIBODY SPECIFICITY; BACULOVIRUS; CHELATING AGENT; COBALT; GLYCOSIDASE; GLYCOSYLATION; IMMUNOASSAY; INSECT CELL; MASS SPECTROMETRY; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN EXPRESSION; RECOMBINANT PROTEIN; TUMOR CELL LINE; TUMOR MARKER;

INSECTA; UNIDENTIFIED BACULOVIRUS;

EID: 0034042053     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1006/prep.2000.1222     Document Type: Article

References (34)

1. Horoszewicz J. S., Kawinski E., Murphy G. P. Monoclonal antibodies to a new antigenic marker in epithelial prostate cells and serum of prostatic cancer patients. Anticancer Res. 7:1987;927-936.
2. Israeli R. S., Powell T., Fair W. R., Heston W. D. W. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 53:1993;227-230.
3. Israeli R. S., Powell T., Corr J. G., Fair W. R., Heston W. D. W. Expression of the prostate-specific membrane antigen. Cancer Res. 54:1994;1807-1811.
4. Troyer J. K., Beckett M. L., Wright G. L. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer. 62:1995;552-558.
5. Wright G. L., Haley C., Beckett M. L., Schellhammer P. F. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol. 1:1995;18-28.
6. Bostwick D. G., Pacelli A., Blute M., Roche P., Murphy G. P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: Study of 184 cases. Cancer. 82:1998;2256-2261.
7. Silver D. A., Pellicer I., Fair W. R., Heston W. D. W., Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3:1997;81-85.
8. Kawakami M., Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 57:1997;2321-2331.
9. Liu H., Moy P., Kim S., Xia Y., Rajasekaran A., Navarro V., Knudsen B., Bander N. H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57:1997;3629-3624.
10. Wright G. L., Grob B. M., Haley C., Grossman K., Newhall K., Petrylak D., Troyer J., Konchuba A., Schellhammer P. F., Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 48:1996;326-334.
11. Sweat S. D., Pacelli A., Murphy G. P., Bostwick D. G. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastasis. Urology. 52:1998;637-640.
12. Murphy G. P., Holmes E. H., Boynton A. L., Kenny G. M., Ostenson R. C., Erickson S. J., Barren R. J. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate. 26:1995;164-168.
13. Murphy G. P., Tino W. T., Holmes E. H., Boynton A. L., Erickson S. J., Bowes V. A., Barren R. J., Tjoa B. A., Misrock S. L., Ragde H., Kenny G. M. Measurement of prostate-specific membrane antigen in the serum with a new antibody. Prostate. 28:1996;266-271.
14. Beckett M. L., Cazares L. H., Vlahou A., Schellhammer P. F., Wright G. L. Prostate specific membrane antigen (PSMA) levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin. Cancer Res. 5:1999;4034-4040.
15. Murphy G. P., Ragde H., Kenny G., Barren R., Erickson S., Tjoa B., Boynton A., Holmes E., Gilbaugh J., Douglas T. Comparison of prostate specific membrane antigen and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. 15:1995;1473-1479.
16. Abdel-Nabi H., Wright G. L., Gulfo J. V., Petrylak D. P., Neal C. E., Texter J. E., Begun F. P., Tyson I., Heal A., Mithell E. Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin. Urol. 10:1992;45-54.
17. Lopes A. D., Davis W. L., Rosenstraus M. J., Uveges A. J., Gilman S. C. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11.C5. Cancer Res. 50:1990;6423-6429.
18. 111In-labeled monoclonal antibody 7E11-C5.3. J. Urol. 152:1994;1952-1955.
19. 111indium-labeled CYT-356 for the detection of occult prostate cancer recurrence. J. Urol. 152:1994;1490-1495.
20. Murphy G. P., Tjoa B., Ragde H., Kenny G., Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 29:1996;371-380.
21. Tjoa B., Boynton A., Kenny G., Ragde H., Misrock S. L., Murphy G. P. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate. 28:1996;65-69.
22. Tjoa B. A., Erickson S. J., Bowes V. A., Ragde H., Kenny G. M., Cobb O. E., Ireton R. C., Troychak M. J., Boynton A. L., Murphy G. P. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate. 32:1997;272-278.
23. Salgaller M. L., Lodge P. A., Mclean J. G., Tjoa B. A., Loftus D. J., Ragde H., Kenny G. M., Rogers M., Boynton A. L., Murphy G. P. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate. 35:1998;144-151.
24. Wright J. L. Jr., Cazares L. H., Leung S-M., Nasim S., Adam B-L., Yip T-T., Schellhammer P. F., Gong L., Vlahou A. Proteinchip surface enhanced laser desorption/ionization (SELDI) mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostate Dis. 2:2000;264-276.
25. Troyer J. K., Feng Q., Beckett M. L., Wright G. L. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol. Oncol. 1:1995;29-37.
26. Hom L. G., Volkman L. E. Preventing artifacts in the baculovirus expression system. Biotechniques. 25:1998;18-20.
27. Crossen R., Gruenwald S. Baculovirus Expression Vector System Manual. 1996;PharMingen, San Diego.
28. Holmes E. H., Greene T. G., Tino W. T., Boynton A. L., Aldape H. C., Misrock S. L., Murphy G. P. Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. Prostate Suppl. 7:1996;25-29.
29. Lodge P. A., Childs R. A., Monahan S. J., McLean J. G., Sehgal A., Boynton A. L., Salgaller M. L., Murphy G. P. Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cells. J. Immunother. 22:1999;346-355.
30. Fraser M. J. The baculovirus-infected insect cell as a eukaryotic gene expression system. Curr. Top. Microbiol. Immunol. 158:1992;131-172.
31. Davis T. R., Schuler M. L., Granados R. R., Wood H. A. Comparison of oligosaccharide processing among various insect cell lines expressing a secreted glycoprotein. In Vitro Cell Dev. Biol. Anim. 29A:1993;842-846.
32. Jarvis D. L., Finn E. E. Biochemical analysis of the N-glycosylation pathway in baculovirus-infected lepidopteran insect cells. Virology. 212:1995;500-511.
33. Nelson R. W., Krone J. R., Bieber A. L., Williams P. Mass spectrometric immunoassay. Anal. Chem. 67:1995;1153-1158.
34. Kuwata H., Yip T. T., Yip C. L., Tomita M., Hutchens T. W. Bactericidal domain of lactoferrin: Detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry. Biochem. Biophy. Res. Commun. 245:1998;764-773.